Here's the Medicaid stock 4 Congress members suspiciously dumped before funding cuts

Centene Corporation (CNC) shares plummeted nearly 40% on July 2 after the company withdrew full-year guidance, citing mounting challenges in its Medicaid and Affordable Care Act (ACA) businesses, including a projected $2.75/share earnings cut due to adverse enrollment and cost trends. This significant downturn coincided with disclosures that four U.S. House members sold CNC shares between May 12 and May 30, weeks prior to both Centene's announcement and the passage of the One Big Beautiful Bill Act (OBBBA), which legislates $1 trillion in Medicaid cuts. The timing of these congressional transactions, involving a company directly impacted by such major legislation, has fueled concerns over potential insider knowledge.

Analysis

Centene Corporation (CNC) experienced a significant valuation shock, with its stock plunging nearly 40% after the company withdrew its full-year guidance on July 2. This decision was attributed to severe challenges within its core Medicaid and Affordable Care Act (ACA) businesses, which are now projected to reduce earnings by $2.75 per share due to adverse enrollment and cost trends. The company's outlook is further darkened by significant legislative headwinds, specifically the newly passed 'One Big Beautiful Bill Act' (OBBBA). This act mandates a $1 trillion reduction in Medicaid funding over the next decade and is expected to remove 10 to 12 million people from coverage, directly eroding Centene's primary customer base. Compounding these issues, Centene is facing a deteriorating risk pool as healthier members disenroll following the end of pandemic-era benefits, leaving the insurer with a more costly patient population and compressing margins. The situation is accompanied by governance concerns, as four U.S. House members sold their positions in CNC weeks before the negative announcement and the passage of the OBBBA, raising questions about the potential use of non-public information.

Key Decisions for Investors

• Given the confluence of a drastic guidance withdrawal, a direct legislative attack on its core Medicaid business via the OBBBA, and deteriorating enrollment trends, the fundamental investment case for Centene has been severely compromised, warranting a highly cautious or bearish stance.
• Investors should closely monitor the implementation of the OBBBA and any subsequent company disclosures on enrollment figures and medical loss ratios, as these will be the primary indicators of the full financial impact.
• The timing of congressional stock sales ahead of major legislative and corporate news introduces a significant governance risk and suggests that downside catalysts may have been anticipated, advising against attempting to 'catch a falling knife' until there is greater clarity on the regulatory and operational fallout.